Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension

References

• Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020 Apr;16(4):223–237. Epub 2020 Feb 5. PMID: 32024986; PMCID: PMC7998524. doi: 10.1038/s41581-019-0244-2
   PubMed Web of Science ®Google Scholar
• Roth GA, Huffman MD, Moran AE, et al. Global and regional patterns in cardiovascular mortality from 1990 to 2013. Circulation. 2015;132(17):1667–1678. doi: 10.1161/CIRCULATIONAHA.114.008720
   PubMed Web of Science ®Google Scholar
• Franco C, Sciatti E, Favero G, et al. Essential hypertension and oxidative stress: novel future perspectives. Int J Mol Sci. 2022 Nov 21;23(22): 14489. PMID: 36430967; PMCID: PMC9692622. doi:10.3390/ijms232214489.
   PubMed Web of Science ®Google Scholar
• Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the dietary Approaches to Stop hypertension (DASH) diet. N Engl J Med. 2001 Jan 4;344(1):3–10. PMID: 11136953. doi:10.1056/NEJM200101043440101
   PubMed Web of Science ®Google Scholar
• Lopes S, Mesquita-Bastos J, Garcia C, et al. Effect of exercise training on ambulatory blood pressure among patients with resistant hypertension: a randomized clinical trial. JAMA Cardiol. 2021 Nov 1;6(11):1317–1323. PMID: 34347008; PMCID: PMC8340008. doi: 10.1001/jamacardio.2021.2735
   PubMed Web of Science ®Google Scholar
• Awosika A, Khan A, Adabanya U, et al. Aldosterone synthase inhibitors and dietary interventions: a combined novel approach for prevention and treatment of cardiovascular disease. Cureus. 2023 Mar 15;15(3):e36184. PMID: 36937127; PMCID: PMC10016316. doi: 10.7759/cureus.36184
   PubMed Web of Science ®Google Scholar
• Schumacher CD, Steele RE, Brunner HR. Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy. J Hypertens. 2013 Oct;31(10):2085–2093. PMID: 24107737; PMCID: PMC3771574. doi: 10.1097/HJH.0b013e328363570c
   PubMed Web of Science ®Google Scholar
• Karns AD, Bral JM, Hartman D, et al. Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension. J Clin Hypertens (Greenwich). 2013 Mar;15(3):186–192. Epub 2012 Dec 14. PMID: 23458591; PMCID: PMC8033888. doi:10.1111/jch.12051
   PubMed Web of Science ®Google Scholar
• Freeman MW, Halvorsen YD, Marshall W, et al. BrigHTN investigators. Phase 2 trial of baxdrostat for treatment-resistant hypertension. N Engl J Med. 2023 Feb 2;388(5):395–405. Epub 2022 Nov 7. PMID: 36342143. doi: 10.1056/NEJMoa2213169
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Rodriguez-Sanchez E, Navarro-Garcia JA, et al. Resistant hypertension: new insights and therapeutic perspectives. Eur Heart J Cardiovasc Pharmacother. 2020;6(3):188–193. doi: 10.1093/ehjcvp/pvz057
   PubMed Web of Science ®Google Scholar
• Dudenbostel T, Ghazi L, Liu M, et al. Body mass index predicts 24-hour urinary aldosterone levels in patients with resistant hypertension. Hypertension. 2016;68(4):995–1003. doi: 10.1161/HYPERTENSIONAHA.116.07806
   PubMed Web of Science ®Google Scholar
• Bogman K, Schwab D, Delporte ML, et al. Preclinical and early clinical profile of a highly selective and potent oral inhibitor of aldosterone synthase (CYP11B2). Hypertension. 2017;69(1):189–196. doi: 10.1161/HYPERTENSIONAHA.116.07716
   PubMed Web of Science ®Google Scholar
• Menard J, Watson C, Rebello S, et al. Hormonal and electrolyte responses to the aldosterone synthase inhibitor LCI699 in sodium depleted healthy subjects. JACC. 2010;55(10):A61.E583. doi: 10.1016/S0735-1097(10)60584-0
   Google Scholar
• Sloan-Lancaster J, Raddad E, Flynt A, et al. LY3045697, a novel, potent, and selective inhibitor of aldosterone synthase, reduces aldosterone levels and shows potential for the treatment of hypertension and cardiovascular diseases. J Clin Pharmacol. 2017;57:65–74.
   Google Scholar
• Schumacher S, Oo YA, Kurtz TW. Antimineralocorticoid therapies for hypertension and heart failure. Hypertension. 2013;62:994–1001.
   Google Scholar
• Martin RE, Aebi JD, Hornsperger B, et al. Discovery of 4-aryl-5,6,7,8-tetrahydroisoquinolines as potent, selective, and orally active aldosterone synthase (CYP11B2) inhibitors: in vivo evaluation in rodents and cynomolgus monkeys. J Med Chem. 5815;58(20):8054–8065. doi: 10.1021/acs.jmedchem.5b00851
   PubMed Web of Science ®Google Scholar
• Mornet E, Dupont J, Vitek A, et al. Characterization of two genes encoding human steroid 11β-hydroxylase (P-45011β). J Biol Chem. 1989;264(35):20961–20967. doi: 10.1016/S0021-9258(19)30030-4
   PubMed Web of Science ®Google Scholar
• Oelkers W. Adrenal insufficiency. N Engl J Med. 1996;335(16):1206–1212. doi: 10.1056/NEJM199610173351607
   PubMed Web of Science ®Google Scholar
• Wagner J, White PC. Abnormalities in corticosteroid synthesis: genetic and phenotypic spectrum. Horm Res. 1984;22:200–210.
   Google Scholar
• Freeman MW, Bond M, Murphy B, et al. Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers. Hypertens Res. 2023 Jan;46(1):108–118. Epub 2022 Oct 20. PMID: 36266539; PMCID: PMC9747611. doi: 10.1038/s41440-022-01070-4
   PubMed Web of Science ®Google Scholar
• Eagle KA Efficacy and safety of baxdrostat in patients with uncontrolled hypertension – HALO [ American College of Cardiology]. Mar 4, 2023. [Cited Sep 26, 2023] American College of Cardiology: https://www.acc.org/latest-in-cardiology/clinical-trials/2023/03/01/23/34/halo
   Google Scholar
• Clinicaltrials.gov. A study to evaluate CIN-107 for the treatment of patients with uncontrolled hypertension and chronic kidney disease. CinCor Pharma, Inc; 2023. [Cited Sep 26, 2023] Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05432167
   Google Scholar
• Clinicaltrials.gov. A study of CIN-107 in adults with primary aldosteronism. CinCor Pharma, Inc; 2023. [Cited Sep 26, 2023] Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04605549
   Google Scholar
• Clinicaltrials.gov. A study to investigate the efficacy and safety of baxdrostat in Participants with uncontrolled hypertension on two or more medications including Participants with resistant hypertension (BaxHTN). CinCor Pharma, Inc; 2023. [Cited Sep 26, 2023] Available from: https://classic.clinicaltrials.gov/ct2/show/NCT06034743
   Google Scholar
• Zhou L, Jiang Y, Zhang C, et al. Effects of a low-sodium diet in patients with idiopathic hyperaldosteronism: a randomized controlled trial. Front Endocrinol PMID: 37152926; PMCID: PMC10154588 2023 Apr 19;14:1124479. doi:10.3389/fendo.2023.1124479
   PubMedGoogle Scholar
• Chen SY, Chen JY, Huang WC, et al. Cardiovascular outcomes and all-cause mortality in primary aldosteronism after adrenalectomy or mineralocorticoid receptor antagonist treatment: a meta-analysis. Eur J Endocrinol. 187(6): PMID: 36315466:S47–S58. 2022 Nov 22. doi:10.1530/EJE-22-0375
   PubMed Web of Science ®Google Scholar
• Parthasarathy HK, Ménard J, White WB, et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens. 2011 May;29(5):980–990. PMID: 21451421. doi: 10.1097/HJH.0b013e3283455ca5
   PubMed Web of Science ®Google Scholar
• Fahed G, Aoun L, Bou Zerdan M, et al. Metabolic syndrome: updates on pathophysiology and management in 2021. Int J Mol Sci. 2022 Jan 12;23(2): 786. PMID: 35054972; PMCID: PMC8775991. doi:10.3390/ijms23020786
   PubMed Web of Science ®Google Scholar
• de Chantemèle EJ B, Mintz JD, Rainey WE, et al. Impact of leptin-mediated sympatho-activation on cardiovascular function in obese mice. Hypertension. 2011 Aug;58(2):271–279. Epub 2011 Jun 20. PMID: 21690486; PMCID: PMC3141100. doi: 10.1161/HYPERTENSIONAHA.110.168427
   PubMed Web of Science ®Google Scholar
• Schäfer N, Lohmann C, Winnik S, et al. Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity. Eur Heart J. 2013 Dec;34(45):3515–3524. Epub 2013 Apr 17. PMID: 23594590; PMCID: PMC3844149. doi: 10.1093/eurheartj/eht095
   PubMed Web of Science ®Google Scholar
• Andronico G, Cottone S, Mangano MT, et al. Insulin, renin-aldosterone system and blood pressure in obese people. Int J Obes Relat Metab Disord. 2001 Feb;25(2):239–242. PMID: 11410826. doi: 10.1038/sj.ijo.0801483
   PubMed Web of Science ®Google Scholar
• Briones AM, Nguyen Dinh Cat A, Callera GE, et al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension. 2012 May;59(5):1069–1078. Epub 2012 Apr 9. PMID: 22493070. doi: 10.1161/HYPERTENSIONAHA.111.190223
   PubMed Web of Science ®Google Scholar
• Goodfriend TL, Egan BM, Kelley DE. Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans. Prostaglandins Leukot Essent Fatty Acids. 1999 May;60(5–6):401–405. PMID: 10471129. doi: 10.1016/s0952-3278(99)80020-9
   PubMed Web of Science ®Google Scholar
• Silva MA, Cau SB, Lopes RA, et al. Mineralocorticoid receptor blockade prevents vascular remodelling in a rodent model of type 2 diabetes mellitus. Clin Sci (Lond). 2015 Oct;129(7):533–545. Epub 2015 May 13. PMID: 25967696. doi: 10.1042/CS20140758
   PubMed Web of Science ®Google Scholar
• Huby AC, Antonova G, Groenendyk J, et al. Adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis. Circulation. [2015 Dec 1];132(22):2134–2145. Epub 2015 Sep 11. PMID: 26362633. doi: 10.1161/CIRCULATIONAHA.115.018226
   PubMed Web of Science ®Google Scholar
• Faulkner JL, Bruder-Nascimento T, de Chantemèle EJ B. The regulation of aldosterone secretion by leptin: implications in obesity-related cardiovascular disease. Curr Opin Nephrol Hypertens. 2018 Mar;27(2):63–69. PMID: 29135585; PMCID: PMC6053669. doi: 10.1097/MNH.0000000000000384
   PubMed Web of Science ®Google Scholar
• Freeman MW, Bond M, Murphy B, et al. Results from a randomized, open-label, crossover study evaluating the effect of the aldosterone synthase inhibitor baxdrostat on the pharmacokinetics of metformin in healthy human subjects. Am J Cardiovasc Drugs. 2023 May;23(3):277–286. Epub 2023 Feb 15. PMID: 36790596; PMCID: PMC9930700. doi: 10.1007/s40256-023-00572-x
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Agarwal R, Anker SD, et al. FIDELIO-DKD investigators. Blood pressure and cardiorenal outcomes with finerenone in chronic kidney disease in type 2 diabetes. Hypertension. 2022 Dec;79(12):2685–2695. Epub 2022 Oct 12. PMID: 36252131; PMCID: PMC9640256. doi: 10.1161/HYPERTENSIONAHA.122.19744
   PubMed Web of Science ®Google Scholar
• Yasuda G, Soleimani M, Lanaspa MA, et al. Aldosterone induced kidney injury is exacerbated in mice lacking Cyp24a1. Kidney Int. 2011;80(8):885–894. doi: 10.1038/ki.2011.272
   Google Scholar
• Wang H, Tian J, Yang K. Efficacy and safety of LCI699 for hypertension: a meta-analysis of randomized controlled trials and systematic review. Eur Rev Med Pharmacol Sci. 2015;19(2):296–304.
   PubMed Web of Science ®Google Scholar
• Sudano I, Ruschitzka F, Noll G, et al. Endothelial function and the effects of aldosterone blockade. Eur Heart J Suppl. 2011 Jul;13:B21–B26. Issue suppl_B. doi: 10.1093/eurheartj/sur010
   Web of Science ®Google Scholar
• Briet M, Barhoumi T, Mian MOR, et al. Aldosterone-induced vascular remodeling and endothelial dysfunction require functional angiotensin type 1a receptors. Hypertension. 2016 May;67(5):897–905. Epub 2016 Apr 4. PMID: 27045029; PMCID: PMC4833572. doi: 10.1161/HYPERTENSIONAHA.115.07074
   PubMed Web of Science ®Google Scholar
• Ferreira NS, Tostes RC, Paradis P, et al. Inflammation, Immune System, and Hypertension. Am J Hypertens. 2021 Jan;34(1):15–27. doi: 10.1093/ajh/hpaa137
   PubMed Web of Science ®Google Scholar
• Brown NJ. Aldosterone and vascular inflammation. Hypertension. 2008 Feb;51(2):161–167. Epub 2008 Jan 2. PMID: 18172061. doi: 10.1161/HYPERTENSIONAHA.107.095489
   PubMed Web of Science ®Google Scholar
• Hung CS, Chou CH, Liao CW, et al. TAIPAI study group*. Aldosterone induces tissue inhibitor of metalloproteinases-1 expression and further contributes to collagen accumulation: from clinical to bench studies. Hypertension. 2016 Jun;67(6):1309–1320. Epub 2016 Apr 25. PMID: 27113051. doi: 10.1161/HYPERTENSIONAHA.115.06768
   PubMed Web of Science ®Google Scholar
• Zannad F, Gattis Stough W, Rossignol P, et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J. 2012 Nov;33(22):2782–2795. Epub 2012 Aug 31. PMID: 22942339. doi: 10.1093/eurheartj/ehs257
   PubMed Web of Science ®Google Scholar
• Monahan KD, Leuenberger UA, Ray CA. Aldosterone impairs baroreflex sensitivity in healthy adults. Am J Physiol Heart Circ Physiol. 2007;292(1):H190–7. doi: 10.1152/ajpheart.00622.2006
   PubMed Web of Science ®Google Scholar
• Acelajado MC, Pimenta E, Calhoun DA. Salt and aldosterone: a concert of bad effects. Hypertension. 2010;56(5):804–805. doi: 10.1161/HYPERTENSIONAHA.110.160960
   PubMed Web of Science ®Google Scholar